Aurisco Pharmaceutical Co.,Ltd. (SHSE:605116) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
Aurisco Pharmaceutical Co.,Ltd. (SHSE:605116) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
It is hard to get excited after looking at Aurisco PharmaceuticalLtd's (SHSE:605116) recent performance, when its stock has declined 14% over the past three months. However, a closer look at its sound financials might cause you to think again. Given that fundamentals usually drive long-term market outcomes, the company is worth looking at. In this article, we decided to focus on Aurisco PharmaceuticalLtd's ROE.
看了奧里斯科製藥有限公司（SHSE: 605116）最近的表現，很難感到興奮，當時其股票在過去三個月中下跌了14％。但是，仔細觀察其穩健的財務狀況可能會讓你重新考慮。鑑於基本面通常會推動長期市場業績，因此該公司值得關注。在本文中，我們決定重點介紹奧里斯科製藥有限公司的投資回報率。
ROE or return on equity is a useful tool to assess how effectively a company can generate returns on the investment it received from its shareholders. In short, ROE shows the profit each dollar generates with respect to its shareholder investments.
投資回報率或股本回報率是評估公司如何有效地從股東那裏獲得投資回報的有用工具。簡而言之，投資回報率顯示了每美元從其股東投資中產生的利潤。
How To Calculate Return On Equity?
如何計算股本回報率？
The formula for return on equity is:
股本回報率的公式是：
Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity
股本回報率 = 淨利潤（來自持續經營業務）÷ 股東權益
So, based on the above formula, the ROE for Aurisco PharmaceuticalLtd is:
因此，根據上述公式，奧里斯科製藥有限公司的投資回報率爲：
14% = CN¥255m ÷ CN¥1.9b (Based on the trailing twelve months to September 2023).
14% = 2.55億元人民幣 ÷ 19億元人民幣（基於截至2023年9月的過去十二個月）。
The 'return' refers to a company's earnings over the last year. That means that for every CN¥1 worth of shareholders' equity, the company generated CN¥0.14 in profit.
“回報” 是指公司去年的收益。這意味着，每獲得價值1元人民幣的股東權益，該公司就會產生0.14元人民幣的利潤。
What Is The Relationship Between ROE And Earnings Growth?
投資回報率與收益增長之間有什麼關係？
Thus far, we have learned that ROE measures how efficiently a company is generating its profits. Based on how much of its profits the company chooses to reinvest or "retain", we are then able to evaluate a company's future ability to generate profits. Assuming everything else remains unchanged, the higher the ROE and profit retention, the higher the growth rate of a company compared to companies that don't necessarily bear these characteristics.
到目前爲止，我們已經了解到，投資回報率衡量的是公司創造利潤的效率。根據公司選擇將多少利潤進行再投資或 “保留”，我們便能夠評估公司未來創造利潤的能力。假設其他一切保持不變，那麼與不一定具有這些特徵的公司相比，投資回報率和利潤保留率越高，公司的增長率就越高。
Aurisco PharmaceuticalLtd's Earnings Growth And 14% ROE
Aurisco PharmaceuticalLTD的收益增長和14％的投資回報率
To start with, Aurisco PharmaceuticalLtd's ROE looks acceptable. Especially when compared to the industry average of 8.3% the company's ROE looks pretty impressive. This certainly adds some context to Aurisco PharmaceuticalLtd's decent 9.6% net income growth seen over the past five years.
首先，奧里斯科製藥有限公司的投資回報率似乎可以接受。特別是與行業平均水平的8.3％相比，該公司的投資回報率看起來相當可觀。這無疑爲Aurisco PharmaceuticalLTD在過去五年中實現的9.6％的淨收入增長增添了一些背景信息。
We then performed a comparison between Aurisco PharmaceuticalLtd's net income growth with the industry, which revealed that the company's growth is similar to the average industry growth of 11% in the same 5-year period.
然後，我們將Aurisco PharmaceuticalLTD的淨收入增長與該行業進行了比較，結果顯示該公司的增長與同期行業11％的平均增長率相似。
Earnings growth is a huge factor in stock valuation. The investor should try to establish if the expected growth or decline in earnings, whichever the case may be, is priced in. This then helps them determine if the stock is placed for a bright or bleak future. One good indicator of expected earnings growth is the P/E ratio which determines the price the market is willing to pay for a stock based on its earnings prospects. So, you may want to check if Aurisco PharmaceuticalLtd is trading on a high P/E or a low P/E, relative to its industry.
收益增長是股票估值的重要因素。無論如何，投資者應設法確定預期的收益增長或下降是否已計入其中。然後，這可以幫助他們確定股票是爲光明還是暗淡的未來而佈局。衡量預期收益增長的一個很好的指標是市盈率，它根據收益前景決定了市場願意爲股票支付的價格。因此，您可能需要檢查Aurisco PharmaceuticalLTD相對於其行業是高市盈率還是低市盈率。
Is Aurisco PharmaceuticalLtd Efficiently Re-investing Its Profits?
Aurisco PharmaceuticalLTD 是否有效地將其利潤再投資？
Aurisco PharmaceuticalLtd has a three-year median payout ratio of 30%, which implies that it retains the remaining 70% of its profits. This suggests that its dividend is well covered, and given the decent growth seen by the company, it looks like management is reinvesting its earnings efficiently.
Aurisco PharmaceuticalLTD的三年派息率中位數爲30％，這意味着它保留了剩餘的70％的利潤。這表明其股息覆蓋範圍良好，鑑於該公司的可觀增長，管理層似乎正在有效地對其收益進行再投資。
Besides, Aurisco PharmaceuticalLtd has been paying dividends over a period of three years. This shows that the company is committed to sharing profits with its shareholders.
此外，Aurisco PharmaceuticalLTD已在三年內派發了股息。這表明該公司致力於與股東分享利潤。
Conclusion
結論
In total, we are pretty happy with Aurisco PharmaceuticalLtd's performance. Particularly, we like that the company is reinvesting heavily into its business, and at a high rate of return. Unsurprisingly, this has led to an impressive earnings growth. Having said that, looking at the current analyst estimates, we found that the company's earnings are expected to gain momentum. To know more about the latest analysts predictions for the company, check out this visualization of analyst forecasts for the company.
總的來說，我們對奧里斯科製藥有限公司的表現非常滿意。特別是，我們喜歡該公司對其業務進行大量再投資，而且回報率很高。毫不奇怪，這帶來了令人印象深刻的收益增長。話雖如此，從分析師目前的估計來看，我們發現該公司的收益有望增強。要詳細了解分析師對公司的最新預測，請查看該公司的分析師預測的可視化。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎？對內容感到擔憂？直接聯繫我們。 或者，給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論，我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議，也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意，我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之，華爾街沒有持有任何上述股票的頭寸。
譯文內容由第三人軟體翻譯。